Gen­mab ax­es an ADC de­vel­op­ment pro­gram af­ter the da­ta fail to im­press

Gen­mab $GMAB has opt­ed to ax one of its an­ti­body-drug con­ju­gates af­ter watch­ing it flop in the clin­ic.

The Dan­ish biotech re­port­ed Tues­day that it de­cid­ed to kill their pro­gram for enapotam­ab ve­dotin af­ter the da­ta gath­ered from ex­pan­sion co­horts failed to mea­sure up. Ac­cord­ing to the com­pa­ny:

While enapotam­ab ve­dotin has shown some ev­i­dence of clin­i­cal ac­tiv­i­ty, this was not op­ti­mized by dif­fer­ent dose sched­ules and/or pre­dic­tive bio­mark­ers. Ac­cord­ing­ly, the da­ta from the ex­pan­sion co­horts did not meet Gen­mab’s strin­gent cri­te­ria for proof-of-con­cept.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER